Rallybio Corporation (RLYB)

NASDAQ: RLYB · USD

$15.9

+0.10 (+0.6%)· Recorded snapshot

Market cap	85.4M
Revenue (ttm)	434K
Net income (ttm)	26.8M
EPS (ttm)	$4.65
Shares out	5.4M
P/E (trailing)	3.4x
Volume	45,762.322
Beta	-0.71

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 434K
Net income (ttm): 26.8M
EPS (ttm): $4.65
P/E (trailing): 3.4x
Market cap: 85.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E3.4

P25 n/aP50 n/aP75 n/a

ROE34.5

P25 n/aP50 n/aP75 n/a

ROIC-17.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All RLYB indicators

Market & fundamental data

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001739410
Company name	Rallybio Corporation
Country	United States
Country code	US
CUSIP number	75120L209
Earnings date	2026-10-27
Earnings time	bmo
Employees	7
Employees change	-13
Employees growth	-65%
Enterprise value	$-5.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
Industry	Biotechnology
IPO date	2021-07-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US75120L2097
Last 10-K release date	2026-03-16
Last earnings date	2026-10-27
Last refreshed	2026-11-04
Last stock split date	2026-02-06
Last stock split type	Reverse
Market cap	$85.4M
Market cap category	Micro-Cap
Next earnings date	2027-03-15
Options	No
Price	$15.86
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-03
Symbol	RLYB
U.S. state	Connecticut
Website	https://www.rallybio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	29.34%
FCF / EV yield	-584.23%
FCF yield	36.29%
Graham number	42.56619
Graham upside	168.39%
P/(FCF - SBC) ratio	2.97x
P/(OCF - SBC) ratio	2.97x
P/B ratio	0.92x
P/E ratio	3.41x
P/FCF ratio	2.76x
P/OCF ratio	2.76x
P/S ratio	196.75x
Price / tangible book value	0.93x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Effective tax rate	4.98%
FCF margin	7,139.63%
Operating margin	-5,050.92%
Pretax margin	6,500.92%
Profit margin	6,177.42%
Profit per employee	$3.8M
Revenue per employee	$62,000
ROA	-16.79%
ROA (5Y)	-28.66%
ROCE	-23.75%
ROE	34.52%
ROE (5Y)	-41.36%
ROIC	-17.62%
SBC / revenue	510.6%
Tax / revenue	323.5%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	2
Revenue growth	-35.61%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$8,000
EBIT	$-21.9M
EBITDA	$-21.9M
EPS	$4.65
FCF per share	$5.76
Financing cash flow	$260,000
Free cash flow	$31M
Free cash flow minus SBC	$28.8M
Gross profit	$-5.8M
Income taxes	$1.4M
Investing cash flow	$27.3M
Net cash flow	$58.6M
Net income	$26.8M
Operating cash flow minus SBC	$28.8M
Operating income	$-21.9M
Revenue	$434,000
Stock-based compensation	$2.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	6.48
Book value per share	$17.31
Debt / equity	0
Long-term assets	$810,000
Long-term liabilities	$0
Net cash (debt)	$90.7M
Net cash / market cap	106.21%
Net cash growth	53.4%
Net debt / equity	-0.98
Net debt / FCF	-2.93
Piotroski F-Score	5
Shareholders' equity	$92.3M
Tangible book value	$92.3M
Tangible book value per share	$17.31
Total assets	$95.6M
Total cash	$90.7M
Total debt	$0
Total liabilities	$3.3M
WACC	0.32%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$94.8M
Current liabilities	$3.3M
Current ratio	28.87
Net working capital	$793,000
Quick ratio	27.63
Working capital	$91.5M
Working capital turnover	0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-2.81%
Dividend yield	0%
Shareholder yield	-2.81%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$15.01
1D price change	0.63%
1M price change	-7.14%
1M total return	-7.14%
1W price change	-0.44%
1W total return	-0.44%
1Y price change	184.28%
1Y return CAGR	184.47%
1Y total return	184.27%
20-day SMA	$16.38
200-day SMA	$13.03
3M price change	-0.44%
3M total return	-0.44%
3Y price change	-51.76%
3Y return CAGR	-21.57%
3Y total return	-51.76%
50-day SMA	$16.69
50-day SMA vs 200-day SMA	50over200
52-week high	$17.57
52-week high date	2026-06-01
52-week low	$3.67
52-week low date	2026-02-17
5Y price change	-89.57%
5Y return CAGR	-36.37%
5Y total return	-89.57%
6M price change	68.54%
6M total return	68.54%
After-hours change	0.5%
After-hours close	$15.86
After-hours price	$15.94
All-time high	$206.24
All-time high date	2021-07-30
All-time low	$1.76
All-time low date	2025-04-08
Average true range (ATR)	$0.55
Average volume	25.8K
Beta (1Y)	0.18
Beta (2Y)	1.04
Beta (5Y)	-0.71
Change from 52-week high	-9.75%
Change from 52-week low	332.15%
Change from all-time high	-92.31%
Change from all-time low	800.62%
Change from open	0.63%
Day's gap	0%
Dollar volume	$725,790
High price	$16.43
Low price	$15.50
Monthly RSI	51.95
Open price	$15.76
Position in 52-week range	38.71%
Premarket change	0%
Premarket close	$15.86
Premarket price	$15.86
Previous close	$15.76
Price vs 150-day SMA	5.67%
Price vs 20-day SMA	-3.16%
Price vs 200-day SMA	21.68%
Price vs 50-day SMA	-5%
Relative volume	1.78
Return from IPO open	-86.71%
Return from IPO price	22%
RSI	40.76
Sharpe ratio	1.54
Sharpe ratio (3Y)	0.22
Sharpe ratio (5Y)	0.03
Sortino ratio	4.38
Sortino ratio (3Y)	0.47
Sortino ratio (5Y)	0.11
Volume	45.8K
Weekly RSI	57.15
YTD price change	188.94%
YTD total return	188.95%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.7M
Float percentage	31.44%
Shares change (QoQ)	-1.43%
Shares change (YoY)	2.81%
Shares held by insiders	21.34%
Shares held by institutions	37.97%
Shares outstanding	5.4M
Short % of float	2.42%
Short % of shares	0.76%
Short ratio	4.8 days

Deeper analysis on RLYB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RLYB report

Is a complete RLYB research report available?

No complete published report is available for Rallybio Corporation (RLYB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Rallybio Corporation (RLYB)

Price

Financial snapshot

Fair-value bridge

Latest news · RLYB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RLYB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RLYB

Frequently asked questions